The Barbara Ann Karmanos Cancer Institute has been awarded a $325,372 grant from U CAN-CER VIVE Foundation. The funds will support cancer research focused on diffuse large B cell lymphoma (DLBCL). The funds will directly support the Circulating Tumor DNA as a Predictive Biomarker of Outcomes of Autologous Stem Cell Transplantation in Relapsed Diffuse Large B cell Lymphoma, led by Dipenkumar Modi, M.D., member of the Hematology Multidisciplinary Team at Karmanos. In this pilot study, Karmanos researchers will measure circulating tumor DNA (ctDNA) to help identify patients who are likely to relapse after autologous stem cell transplantation.
Focus of Study
The study’s principal investigator, Dipenkumar Modi, shared his perspective on this condition, stating: "Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin’s lymphoma (NHL). Approximately 30 percent of patients with this disease experience a relapse after standard treatment. About half of the patients with disease relapse achieve durable remission when treated with salvage chemoimmunotherapy followed by autologous stem cell transplantation. Currently, the available methods are not highly sensiti...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).